Drug Profile
PF 07265807
Alternative Names: ARRY-067; PF-07265807; PF-5807Latest Information Update: 06 Jun 2025
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antineoplastics; Small molecules
- Mechanism of Action Axl receptor tyrosine kinase inhibitors; Proto-oncogene protein c-mer inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 25 May 2025 Pfizer terminates a phase I for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Japan, Italy, Australia, Canada, China, South Korea, Spain (unspecified route) based on business decision (NCT04458259)
- 02 May 2023 Discontinued - Phase-I for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Japan, Italy, Australia, Canada, China, South Korea, Spain (unspecified route) (NCT04458259)
- 02 May 2023 Discontinued - Phase-I for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (unspecified route)